Which population groups should be targeted for cardiovascular prevention? A modelling study based on the Norwegian Hordaland Health Study (HUSK)

References

• Rose G. Sick individuals and sick populations. Int J Epidemiol 1985; 14: 32–8
   PubMed Web of Science ®Google Scholar
• Jackson R, Harper S. Preventing coronary heart disease. BMJ 2006; 332: 617–8
   PubMedGoogle Scholar
• Manuel D, Lim J, Tanuseputro P, Anderson GM, Alter DA, Laupacis A, et al. Revisiting Rose: Strategies for reducing coronary heart disease. BMJ 2006; 332: 359–62
   Google Scholar
• Wald N, Law M. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419
   PubMed Web of Science ®Google Scholar
• De Backer G, Amrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. Third Joint Task Force in European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601–10
   PubMed Web of Science ®Google Scholar
• Mosca, L, Apple, LJ, Benjamin, EJ, Berra, K, Chandra-Strobos, N, Fabunmi, RP, et al. Evidence-based guidelines for cardiovascular disease prevention in women. J Am Coll Cardiol 2004;900–21.
   PubMedGoogle Scholar
• Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation 2002; 105: 310–15
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97
   PubMedGoogle Scholar
• New Zealand Guideline Group. Assessment and management of cardiovascular risk 2003. Available at: http://www.nzgg.org.nz/ ( accessed 22 April 2006).
   Google Scholar
• Getz, L, Sigurdsson, JA, Hetlevik, I, Kirkengen, AL, Romundstad, S, Holmen, J. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: Modelling study. BMJ 2005. doi:10.1136/bmj.38555.648623.8F (published 15 August 2005).
   Google Scholar
• Hartz I, Njølstad I, Eggen AE. Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults who need cardiovascular drugs for primary prevention? The Tromsø study 2001. Eur Heart J 2005; 26: 2673–80
   PubMed Web of Science ®Google Scholar
• Philips L, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, et al. Clinical inertia. Ann Intern Med 2001; 135: 825–34
   PubMed Web of Science ®Google Scholar
• Westin S, Heath I. Thresholds for normal blood-pressure and serum cholesterol. BMJ 2005; 330: 1461–2
   PubMed Web of Science ®Google Scholar
• Getz L, Kirkengen AL, Hetlevik I, Sigurdsson JA. Individually based preventive medical recommendations – are they sustainable and responsible?. Scand J Prim Health Care 2005; 23: 65–7
   PubMed Web of Science ®Google Scholar
• University of Bergen. Helseundersøkelsen i Hordaland. Available at: http://www.uib.no/isf/husk, , (accessed 29 June 2006).
   Google Scholar
• Anderson K, Wilson PWF, Odell PM. An updated coronary risk profile: A statement for health professionals. Circulation 1991; 83: 356–62
   PubMed Web of Science ®Google Scholar
• Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, et al. Predictive accuracy of the Framingham coronary risk score in British men: Prospective cohort study. BMJ 2003; 327: 1267
   PubMed Web of Science ®Google Scholar
• Conroy R, Pyörälä K, Fitzgerald AP, Sans S, De Backer G, De Bacquer P, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003; 24: 987–1003
   PubMed Web of Science ®Google Scholar
• Soegaard A, Selmer R, Bjertness E, Thelle D. The Oslo Health Study: The impact of self-selection in a large, population based survey. Int J Equity Health 2004; 3: 1–28
   PubMedGoogle Scholar
• Available at: http://www.uib.no/isf/husk/Vedlegg dokumenter/FrafallsanalyseHUSK9799 ( accessed 29 September 2006)
   Google Scholar
• Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amoyel P. Contributions of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353: 1547–57
   PubMed Web of Science ®Google Scholar
• Hunink M, Goldman KL, Tosteson A, Mittleman M, Goldman P, Williams L. The recent decline in mortality from CHD, 1980–1990. JAMA 1997; 277: 535–42
   PubMed Web of Science ®Google Scholar
• Unal B, Alison J, Critchley A, Capewell A. Modeling the decline in coronary heart disease deaths in England and Wales, 1980–2000: Comparing contribution from primary prevention and secondary prevention. BMJ 2005; 331: 614–17
   PubMed Web of Science ®Google Scholar
• Tunstall-Pedoe H, Connaghan J, Woodward M, Tolonen H, Kuulasmaa K. Pattern of declining blood pressure across replicate population surveys of the WHO MONICA project, mid-1980s to mid-1990s, and the role of medication. BMJ 2006; 332: 629–32
   PubMed Web of Science ®Google Scholar
• Bjartveit K, Stensvold I, Lund-Larsen PG, Graff-Iversen S. Cardiovascular disease prevention programmes in Norwegian counties (English summary). Tidsskr Nor Lægeforen 1991; 111: 2072–6
   PubMedGoogle Scholar
• Wøien G, Øyen O, Graff-Iversen S. 22 years of cardiovascular surveys in Norwegian counties: Is the development in risk factors satisfactory? (English summary). Nor J Epidemiol 1997; 7: 255–66
   Google Scholar
• Lloyd-Jones DM, Tian L. Predicting cardiovascular risk. So what do we do now?. Arch Intern Med 2006; 166: 1342–4
   PubMedGoogle Scholar
• Manuel DG, Kwong K, Tanuseputro P, Lim J, Mustard CA, Anderson GM, et al. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: Modelling study. BMJ 2006; 332: 1419–22
   PubMedGoogle Scholar
• Walley, T, Follino-Gallo, P, Schwabe, U, van Ganse, E, on behalf of the EutoMedStat Group. Variations and increase in use of statins across Europe: Data from administrative databases. BMJ 2004;328:385–6.
   PubMed Web of Science ®Google Scholar
• Hartz I, Njølstad I, Furu K, Skurtveit S, Eggen AE. Why do sales of lipid-lowering drugs vary between counties in Norway?. Scand J Prim Health Care 2006; 24: 115–21
   PubMed Web of Science ®Google Scholar
• Hartz I, Eggen AE, Grimsgaard S, Skjold F, Njølstad I. Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: The Tromsø Study 2001. Eur J Clin Pharmacol 2004; 60: 643–9
   PubMed Web of Science ®Google Scholar
• Tonstad S, Rosvold E, Furu K, Skurtveit S. Undertreatment and overtreatment with statins: the Oslo Health Study 2000–2001. J Intern Med 2004; 255: 494–502
   PubMed Web of Science ®Google Scholar
• Rønning M. Drug consumption in Norway 1998–2003. WHO Collaborating Centre for Drug Statistics and Methdology, Oslo 2003
   Google Scholar
• British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80(Suppl 2)1–29
   PubMedGoogle Scholar
• Treatment and prevention of coronary heart disease by cholesterol lowering therapy: Consensus cholesterol, second revision (in Dutch). Utrecht: CBO; 1998.
   Google Scholar